

Prescribing Clinical Network

|  |   |
|--|---|
| <b>Policy Statement</b>  | Alemtuzumab (Lemtrada) for the treatment of patients with Severe Aplastic Anaemia   |
| <b>Policy Number</b>   | PCN 331-2018  |
| <b>Date of Issue</b>   | April - 2018  |
| <b>Review Date:</b>  | April - 2021<br><i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i> |
| <p><b>Recommendations:</b><br/>The Prescribing Clinical Network does not routinely recommend alemtuzumab (Lemtrada) as a treatment option in the treatment of severe aplastic anaemia in patients who are refractory to immunosuppressive therapy (IST) and where there is no suitably matched donor for haematopoietic stem cell transplantation (HSCT).</p> <p>Alemtuzumab (Lemtrada) will be considered <b>RED</b> on the traffic light system and specialists will be required to apply for funding through the Individual Funding Request (IFR) process if clinical exceptionality can be demonstrated.</p> |   |
| <p><b>Key Considerations:</b></p> <ul style="list-style-type: none"> <li>British society of Haematology Guidelines for the diagnosis and management of aplastic anaemia (December 2016) <a href="https://b-s-h.org.uk/">https://b-s-h.org.uk/</a></li> <li>Unlicensed (off label) use for this indication.</li> </ul>  |   |
| <b>Date taken to Prescribing Clinical Network</b>  | 4 <sup>th</sup> April 2018  |
| <b>Agreed by PCN members</b>   | 13 <sup>th</sup> April 2018   |

*Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG*